Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eluminate-2: Elecoglipron vs Semaglutide in Type 2 Diabetes Mellitus
NCT07662213Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- Jul 2026
- Primary completion
- May 2028
- Countries
- 15
01
Overview
A Phase 3 trial of elecoglipron in type 2 diabetes mellitus (T2DM), sponsored by AstraZeneca. Started Jul 2026; status: recruiting.
02
Drugs
elecoglipron
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07662213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07662213.